Literature DB >> 9398176

An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor.

J L Hessler1, R J Kreitman.   

Abstract

During the intoxication process, Pseudomonas exotoxin (PE) and immunotoxins containing PE internalize into the target cell and become processed into two fragments, and the carboxyl fragment translocates into the cytosol where it inactivates elongation factor 2. We have proposed that after internalization into cells the carboxyl-terminal fragment of PE (amino acids 280-613), which ends in REDLK, binds to the KDEL receptor (ERD2) which carries it to the endoplasmic reticulum, from which the PE fragment translocates to the cytosol. Earlier experiments showing that REDL but not REDLK binds to the KDEL receptor suggested that the terminal lysine is removed sometime during the intoxication process. To determine if and where this occurs, we exposed a peptide ending in REDLK to malignant cells in culture and found that binding to the KDEL receptor was restored. Restoration of receptor binding also occurred if a peptide or toxin ending in REDLK at its carboxyl terminus was incubated with plasma, indicating that the terminal lysine is removed prior to entry of the toxin into the cell. We conclude that plasma carboxypeptidase(s) cleave(s) the lysine residue from the carboxyl terminus of PE and PE-containing immunotoxins as an early and essential step in their cellular intoxication pathway.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398176     DOI: 10.1021/bi971447w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.321


  27 in total

Review 1.  Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Clin Cancer Res       Date:  2011-10-15       Impact factor: 12.531

Review 2.  Immunotoxins for targeted cancer therapy.

Authors:  Robert J Kreitman
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

Review 3.  Alternate routes for drug delivery to the cell interior: pathways to the Golgi apparatus and endoplasmic reticulum.

Authors:  Maria Teresa Tarragó-Trani; Brian Storrie
Journal:  Adv Drug Deliv Rev       Date:  2007-06-28       Impact factor: 15.470

4.  Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.

Authors:  Roberta Traini; Robert J Kreitman
Journal:  Bioconjug Chem       Date:  2011-03-16       Impact factor: 4.774

Review 5.  Bacteria-Host Crosstalk: Sensing of the Quorum in the Context of Pseudomonas aeruginosa Infections.

Authors:  Maria V Turkina; Elena Vikström
Journal:  J Innate Immun       Date:  2018-11-14       Impact factor: 7.349

6.  Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.

Authors:  John F Langenheim; Wen Y Chen
Journal:  Breast Cancer Res Treat       Date:  2005-04       Impact factor: 4.872

7.  Novel cholix toxin variants, ADP-ribosylating toxins in Vibrio cholerae non-O1/non-O139 strains, and their pathogenicity.

Authors:  Sharda Prasad Awasthi; Masahiro Asakura; Nityananda Chowdhury; Sucharit Basu Neogi; Atsushi Hinenoya; Hossain M Golbar; Jyoji Yamate; Eiji Arakawa; Toshiji Tada; T Ramamurthy; Shinji Yamasaki
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

Review 8.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

9.  Mesencephalic astrocyte-derived neurotrophic factor (MANF) secretion and cell surface binding are modulated by KDEL receptors.

Authors:  Mark J Henderson; Christopher T Richie; Mikko Airavaara; Yun Wang; Brandon K Harvey
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

Review 10.  Immunoconjugates in the management of hairy cell leukemia.

Authors:  Robert J Kreitman; Ira Pastan
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-09       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.